Načítá se...
The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan
Heart failure (HF) is one of the leading causes of morbidity, mortality, and health care expenditures in the US and worldwide. For three decades, the pillars of treatment of HF with reduced ejection fraction (HFrEF) were medications that targeted the sympathetic nervous system (SNS) and the renin-an...
Uloženo v:
| Vydáno v: | Arch Med Sci |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Termedia Publishing House
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5575222/ https://ncbi.nlm.nih.gov/pubmed/28883863 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/aoms.2017.68813 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|